Pharming (ADR) (PHAR)
Commercializes rare-disease medicines while advancing a mitochondrial-disease program.
Something off on this page? Send us feedback.
Sells RUCONEST for acute hereditary angioedema attacks and Joenja for activated PI3Kδ syndrome. The commercial portfolio is concentrated in these two medicines, with napazimone in a pivotal study for primary mitochondrial disease.
Commercializes RUCONEST, a recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks, and Joenja, an oral selective PI3Kδ inhibitor for activated phosphoinositide 3-kinase delta syndrome. Its commercial base is concentrated in these two rare-disease medicines.
Operates from Leiden, the Netherlands, with a rare-disease focus. RUCONEST is produced by making the recombinant protein in milk from transgenic rabbits; Joenja came from a global licence from Novartis.
Advances napazimone (KL1333), acquired through Abliva, in a pivotal study for primary mitochondrial disease. Product approvals, patient access, and clinical-pipeline execution shape the business.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| May 8, 2026 | Oppenheimer | Target | $42 | $40 |
| Apr 10, 2026 | Canaccord Genuity | Target | $37 | |
| Mar 12, 2026 | H.C. Wainwright | Target | $37 | |
| Nov 7, 2025 | Oppenheimer | Target | $42 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $158.3M · Total debt $113.3M · Total assets $468.0M · Shareholders' equity $270.5M
- Revenue
- $90.2M
- Operating income
- −$111.0K
- Net income
- $1.6M
No dividends on record.
| Institutions18 holders · as of Jun 30, 2026 | 3.20% | 2.24M ADS |
institutions as of Jun 30, 2026 · holders as of their latest filing
No reliable share count is available for this listing, so stakes are shown as shares, not percentages.
The institutional percentage is the one reported with the filings, not one recomputed on the share count here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Mac Alpha Capital Management, LPInstitution | — | 2.15M ADS | 13Fas of Jun 30, 2026 |
Silverberg Bernstein Capital Management LLCInstitution | — | 41,547 ADS | 13Fas of Jun 30, 2026 |
Crossmark Global Holdings, Inc.Institution | — | 12,463 ADS | 13Fas of Jun 30, 2026 |
Citadel Advisors LLCInstitution | — | 11,972 ADS | 13Fas of Jun 30, 2026 |
Morgan StanleyInstitution | — | 11,500 ADS | 13Fas of Jun 30, 2026 |
| See all 19 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Takeda (ADR)
HAE prevention therapy with TAKHZYRO
- BioCryst Pharmaceuticals
Once-daily oral prophylaxis for hereditary angioedema
- Ionis Pharmaceuticals
RNA-targeted HAE prevention with DAWNZERA
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pharming (ADR) | $11.21 | +0.72% | $792.7M | 87.5 | 55.7 | 2.2 | −18.4% |
| Takeda (ADR) | $18.73 | +1.55% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| BioCryst Pharmaceuticals | $10.17 | −0.10% | $2.58B | — | 19.4 | 2.7 | +33.6% |
| Ionis Pharmaceuticals | $60.74 | −0.93% | $10.19B | — | — | 11.7 | −40.7% |
| Median | 51.2 | 38.1 | 2.7 | +5.8% |